Technical Analysis for CASI - CASI Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.31 0.30% 0.01
CASI closed up 1.54 percent on Monday, March 18, 2019, on 69 percent of normal volume.

Earnings due: Mar 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CASI trend table...

Date Alert Name Type % Chg
Mar 18 MACD Bullish Signal Line Cross Bullish 0.30%
Mar 15 Shooting Star Candlestick Bearish 1.85%
Mar 15 Lizard Bearish Bearish Day Trade Setup 1.85%
Mar 15 Pocket Pivot Bullish Swing Setup 1.85%
Mar 15 Doji - Bearish? Reversal 1.85%
Mar 14 NR7 Range Contraction 2.48%
Mar 14 Down 3 Days in a Row Weakness 2.48%
Mar 12 Spinning Top Other 0.61%
Mar 12 Oversold Stochastic Weakness 0.61%
Mar 11 Stochastic Buy Signal Bullish -0.90%

Older signals for CASI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Biotechnology Cancer Life Sciences Pharmaceutical Diseases Treatment Of Cancer Autoimmune Diseases Multiple Myeloma Cancer Treatment Leukemia Cyclacel Pyrrolidines Advanced Solid Tumors Pacritinib
Is CASI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.89
52 Week Low 2.73
Average Volume 210,694
200-Day Moving Average 5.0073
50-Day Moving Average 3.5216
20-Day Moving Average 3.373
10-Day Moving Average 3.259
Average True Range 0.1678
ADX 10.87
+DI 17.8212
-DI 17.9746
Chandelier Exit (Long, 3 ATRs ) 3.3266
Chandelier Exit (Short, 3 ATRs ) 3.6034
Upper Bollinger Band 3.7056
Lower Bollinger Band 3.0404
Percent B (%b) 0.39
BandWidth 19.721316
MACD Line -0.083
MACD Signal Line -0.0885
MACD Histogram 0.0055
Fundamentals Value
Market Cap 198.65 Million
Num Shares 60.2 Million
EPS -0.13
Price-to-Earnings (P/E) Ratio -25.38
Price-to-Sales 0.00
Price-to-Book 7.28
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.47
Resistance 3 (R3) 3.45 3.38 3.44
Resistance 2 (R2) 3.38 3.34 3.39 3.43
Resistance 1 (R1) 3.34 3.31 3.36 3.36 3.42
Pivot Point 3.27 3.27 3.28 3.28 3.27
Support 1 (S1) 3.23 3.23 3.25 3.25 3.18
Support 2 (S2) 3.16 3.20 3.17 3.17
Support 3 (S3) 3.12 3.16 3.16
Support 4 (S4) 3.14